Ping-Shang Wu Dan Xiong Yang-Bo Feng Luan Xiang Jian Zhu
10.3389/fimmu.2022.939873
Front Immunol
2022 Aug 25;13:939873.
camrelizumab immunotherapy lung adenocarcinoma mastitis programmed cell death protein 1
CC BY
https://pubmed.ncbi.nlm.nih.gov/36090986/
Adenocarcinoma of Lung / drug therapy Lung Neoplasms / complications Lung Neoplasms / drug therapy Mastitis Pleural Effusion
Adenocarcinoma of Lung / drug therapy Lung Neoplasms / complications Lung Neoplasms / drug therapy Mastitis Pleural Effusion Case Reports Research Support, Non-U.S. Gov't Aged Antibodies, Monoclonal, Humanized Cell Proliferation Female Humans Antibodies, Monoclonal, Humanized camrelizumab
PMC9452652
36090986
Case report: A case of acute mastitis associated with reactive cutaneous capillary endothelial proliferation after camrelizumab treatment: A new immune-related adverse event
2022